Natural Compound Derived From Pomegranates Boosts Heart Function by 80 Percent in Experimental Models of Difficult-to-Treat Heart Failure

Researchers at King’s College London have published a groundbreaking study in the peer-reviewed journal Science Advances detailing how urolithin A—a natural metabolite produced by the human body after the consumption of specific dietary items such as pomegranates, walnuts, and select berries—can dramatically improve cardiac relaxation, mitigate pathological scarring, and suppress harmful ventricular hypertrophy in experimental models of a notoriously stubborn cardiovascular condition.

The findings offer a glimmer of hope for nearly half a million individuals across the United Kingdom, and millions more globally, who suffer from heart failure with preserved ejection fraction (HFpEF). Unlike traditional forms of heart failure where the heart muscle weakens and struggles to force blood outward, HFpEF presents a paradox: the heart retains its mechanical pumping capacity, yet the muscle walls become abnormally stiff. This rigidity prevents the ventricles from relaxing adequately between contractions, severely impairing the organ’s ability to fill with blood and precipitating systemic circulatory inefficiencies.

Accounting for roughly half of all diagnosed heart failure cases, HFpEF is characterized clinically by debilitating symptoms including chronic fatigue, profound shortness of breath, a severely restricted capacity for physical exertion, and an overall degradation of patient quality of life. Despite its high prevalence and severe morbidity, the medical community has struggled for decades to establish effective therapeutic interventions. The condition is biologically complex, frequently intertwined with aging, metabolic syndrome, diabetes, and arterial hypertension. Because standard pharmaceutical treatments designed to assist weak heart muscles fail to address the underlying stiffness of HFpEF, modern clinical management has largely been restricted to lifestyle modifications, weight optimization, and the aggressive control of co-morbidities.

Unlocking the Molecular Mechanism of Urolithin A

To better understand how dietary byproducts might interact with cardiac tissue, the research team at King’s College London focused on urolithin A, a compound that has generated substantial scientific interest in recent years due to its well-documented associations with healthy cellular aging, longevity, and mitochondrial optimization—the cellular energy-generation process.

In a significant scientific breakthrough, the investigators discovered that urolithin A directly interacts with and activates a critical intracellular enzyme known as PKG1α. This specific protein plays a fundamental regulatory role in vascular tone management and the active relaxation of cardiac muscle fibers. Specifically, urolithin A targets a precise amino acid residue within the PKG1α protein, successfully triggering an intracellular signaling cascade that yields profound cardiovascular benefits.

When tested in rigorous experimental animal models, administration of urolithin A yielded an astonishing improvement in overall measures of heart function, boosting performance by as much as 80 percent compared to untreated control models. Furthermore, comprehensive laboratory analyses revealed that the compound successfully enhanced the physical compliance of heart tissue, allowing it to relax more fluidly. It also demonstrably reduced cardiac fibrosis—the accumulation of excessive extracellular matrix proteins that creates harmful scar tissue and further stiffens the myocardium—while limiting the abnormal enlargement of individual heart muscle cells.

From Animal Models to Engineered Human Tissue

Recognizing the translational hurdles inherent in preclinical cardiovascular research, the King’s College London team sought to validate their findings using advanced human cellular models. They tested urolithin A on engineered human heart tissue constructs meticulously generated from human stem cells. These sophisticated laboratory models accurately mimic the complex three-dimensional architecture, electrophysiology, and mechanical function of native human myocardium.

The results mirrored the animal trials: urolithin A significantly enhanced tissue relaxation within the engineered human constructs. This vital step bridges the gap between basic laboratory science and potential clinical application, suggesting that the cardioprotective mechanisms observed in preclinical trials may reliably translate to human physiology.

Crucially, urolithin A possesses a distinct translational advantage over many synthetic experimental molecules: it has already undergone preliminary human safety evaluations in other contexts, demonstrating an exceptionally favorable safety and tolerability profile. While comprehensive human clinical trials remain an absolute prerequisite before any therapeutic claims can be made for heart failure patients, the identification of this naturally derived compound and its specific molecular target marks a major milestone in cardiovascular pharmacology.

Expert Perspectives and Institutional Reactions

Dr. Joseph Burgoyne, a prominent cardiovascular scientist at King’s College London and senior author of the study, emphasized both the promise and the current limitations of the discovery. Dr. Burgoyne’s broader research program focuses on elucidating the molecular mechanisms that regulate vascular and cardiac health, specifically examining how cellular responses to oxidative stress dictate blood pressure regulation and myocardial performance.

"This type of heart failure remains one of the most challenging forms of heart disease to treat," Dr. Burgoyne stated. "Our findings identify a completely new therapeutic target and show that urolithin A can activate this pathway to improve heart relaxation and reduce disease severity. This raises the exciting possibility of developing new treatments that improve clinical outcomes and quality of life for people living with the condition."

At the same time, Dr. Burgoyne issued a cautionary note regarding dietary interpretation: "While there isn’t enough evidence to suggest that people should eat pomegranates to treat heart failure, these findings raise the possibility that dietary approaches that enhance urolithin A production may help alleviate this condition."

The research was funded by the British Heart Foundation (BHF), reflecting the organization’s ongoing commitment to solving the persistent clinical challenges posed by heart failure syndromes. Professor James Leiper, Director of Research at the British Heart Foundation, underscored the public health significance of the study while contextualizing its current standing within the broader medical pipeline.

"Heart failure with preserved ejection fraction makes up roughly half of all heart failure cases in the UK, and can be debilitating," Professor Leiper noted. "This early-stage study in experimental models suggests that urolithin A may help to improve the heart tissue’s ability to relax and fill with blood between beats, reducing the harmful changes to the heart muscle seen in HFpEF."

However, Professor Leiper reiterated the necessity of patience as the scientific community advances toward clinical validation. "While these findings are promising, the benefits have so far been seen in animals and engineered human tissue, so clinical trials involving people are needed to test if this approach is effective for patients. In the meantime, a healthy, balanced diet remains one of the best ways to look after your heart. Eating plenty of fruit and vegetables is linked to better heart health, but it’s important to remember that no single food can prevent or treat heart disease on its own."

Implications for the Future of Cardiovascular Medicine

The publication of this study in Science Advances opens several critical avenues for future research and drug development in cardiology. As populations globally continue to age, and as the global incidence of metabolic disorders such as type 2 diabetes and obesity climbs, the prevalence of HFpEF is projected to accelerate sharply over the coming decades. Without targeted pharmacological therapies, healthcare systems will face an escalating burden of hospitalizations and chronic morbidity associated with the condition.

The identification of PKG1α as a viable therapeutic target via urolithin A activation provides medicinal chemists with a precise blueprint for the design of novel therapeutics. Whether future interventions rely on purified, pharmaceutically optimized formulations of urolithin A, synthetic analogues designed to maximize receptor affinity, or specialized dietary interventions aimed at enhancing the gut microbiome’s natural capacity to convert ellagitannins (found in pomegranates and berries) into urolithin A, the therapeutic landscape for HFpEF is poised for potential transformation.

For now, the medical consensus remains rooted in rigorous clinical evaluation. As researchers design the human clinical trials necessary to test the efficacy of urolithin A in actual HFpEF patients, the scientific community continues to validate the intricate biochemical connections between dietary metabolites and cellular health, bringing medicine one step closer to resolving one of cardiology’s most persistent mysteries.